awmsg logo



vinorelbine (Navelbine®)


Reference No. 330

Publication date:
20/11/2007


Appraisal information

vinorelbine (Navelbine®) capsule


Company: Pierre Fabre Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 12/09/2007
AWMSG meeting date: 18/10/2007
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1007
Ministerial ratification: 15/11/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Oral vinorelbine (Navelbine®) is recommended for use within NHS Wales as a single agent (in line with current NICE recommendations for IV vinorelbine), for the treatment of advanced breast cancer stage III and IV relapsing after or refractory to an anthracycline-containing regimen. Oral vinorelbine (Navelbine®) should only be initiated by specialists experienced in the treatment of breast cancer. Oral vinorelbine (Navelbine®) should not presently be recommended for shared care.
Final Appraisal Recommendation (FAR)
Download